Vir Biotechnology Enters Material Definitive Agreement
Ticker: VIR · Form: 8-K · Filed: 2024-08-01T00:00:00.000Z
Sentiment: neutral
Topics: material-definitive-agreement, new-contract
TL;DR
Vir Bio signed a big deal, details TBD.
AI Summary
On July 31, 2024, Vir Biotechnology, Inc. entered into a material definitive agreement. The filing does not disclose the specific details of this agreement, such as the counterparty or the financial implications.
Why It Matters
This filing indicates a significant new contract or partnership for Vir Biotechnology, the details of which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Registrant
- July 31, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Vir Biotechnology?
The filing states that Vir Biotechnology, Inc. entered into a material definitive agreement on July 31, 2024, but does not provide specific details about the agreement itself.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the material definitive agreement.
What is the effective date of this material definitive agreement?
The earliest event reported is July 31, 2024, which is also the date of the report and the date as of which the change is reported, indicating the agreement was entered into on or around this date.
Are there any financial terms or obligations associated with this agreement mentioned in the filing?
No specific financial terms, amounts, or obligations related to the material definitive agreement are disclosed in this 8-K filing.
Does this filing provide any information on the strategic importance or expected impact of this agreement?
The filing only states that a material definitive agreement was entered into; it does not provide any context regarding its strategic importance or expected impact.
From the Filing
0001193125-24-191500.txt : 20240801 0001193125-24-191500.hdr.sgml : 20240801 20240801160853 ACCESSION NUMBER: 0001193125-24-191500 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240731 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20240801 DATE AS OF CHANGE: 20240801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 241166681 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 d880653d8k.htm 8-K 8-K false 0001706431 0001706431 2024-07-31 2024-07-31     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024     Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter)       Delaware   001-39083   81-2730369 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of principal executive offices, including zip code) (415) 906-4324 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value   VIR   Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2024, Vir Biotechnology, Inc. (the “Company” or “Vir”) and Amunix Pharmaceuticals, Inc., a Sanofi company (“Sanofi”) entered into a License Agreement (the “Agreement”). Upon closing of the transaction contemplated by the Agreement (the “Closing” and the “Transaction”, respectively), the Company will obtain an exclusive (even as to Sanofi and its affiliates), worldwide, royalty-bearing, sublicensable (through multiple tiers in accordance with the Agreement), transferable (to the extent permitted under th